Domainex Announces the Release of Its Latest Generation LeadBuilder Virtual Screening Platform
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Domainex Ltd has released the next generation of its LeadBuilder virtual screening technology. LeadBuilder is the proprietary lead generation platform developed by Domainex to provide rapid access to high-quality small-molecule drug leads, particularly against novel or difficult target proteins. As such, it is well-suited to the needs of both university groups engaged in Translational Research and to emerging biotechnology and pharmaceutical companies.
LeadBuilder employs proprietary search methods to interrogate a vast database of commercially-available compounds with target-specific queries. These queries are defined by using protein or ligand derived information - or ideally by combining knowledge from both of these sources.
The latest enhancements to LeadBuilder include an expanded database of over six million commercial compounds, and the incorporation of a number of software upgrades. Compounds which Domainex selects using LeadBuilder are purchased and tested in biochemical assays to give hit rates which are typically between 1-10%: i.e. three orders of magnitude better than random, high-throughput screening (HTS). Critically, in contrast to HTS, LeadBuilder compounds make screening hits, as they are rich in pharmacophoric features and possess favourable molecular properties combined with predictions of ADME and toxicity profiles.
Dr Trevor Perrior, Research Director of Domainex, commented: “It is generally agreed that one of the most influential factors in determining whether or not a drug research project will be successful is the quality of the starting point, which is usually a screening hit. By using LeadBuilder, we can make high-quality hits available to everyone without them needing to make an investment in the time and expense of high-throughput screening. The latest generation LeadBuilder has been successfully validated on several targets - both for clients such as Breakthrough Breast Cancer, and for Domainex’s internal pipeline - and we look forward to working with this powerful technology on our customers’ drug discovery projects”.
LeadBuilder employs proprietary search methods to interrogate a vast database of commercially-available compounds with target-specific queries. These queries are defined by using protein or ligand derived information - or ideally by combining knowledge from both of these sources.
The latest enhancements to LeadBuilder include an expanded database of over six million commercial compounds, and the incorporation of a number of software upgrades. Compounds which Domainex selects using LeadBuilder are purchased and tested in biochemical assays to give hit rates which are typically between 1-10%: i.e. three orders of magnitude better than random, high-throughput screening (HTS). Critically, in contrast to HTS, LeadBuilder compounds make screening hits, as they are rich in pharmacophoric features and possess favourable molecular properties combined with predictions of ADME and toxicity profiles.
Dr Trevor Perrior, Research Director of Domainex, commented: “It is generally agreed that one of the most influential factors in determining whether or not a drug research project will be successful is the quality of the starting point, which is usually a screening hit. By using LeadBuilder, we can make high-quality hits available to everyone without them needing to make an investment in the time and expense of high-throughput screening. The latest generation LeadBuilder has been successfully validated on several targets - both for clients such as Breakthrough Breast Cancer, and for Domainex’s internal pipeline - and we look forward to working with this powerful technology on our customers’ drug discovery projects”.
